ASH 2014: Younger AML Patients Get Some Benefit from Sorafenib

The drug sorafenib was effective in treating young patients with acute myeloid leukemia (AML) but not effective in terms of overall survival, according to a presentation at the 56th annual meeting of the American Society of Hematology (ASH).

Data from the SORAML trial was presented at the meeting, which enrolled 276 patients between 18 and 60 with AML. Patients were first put into remission with standard induction therapy. They also had consolidation therapy with high-dose cytarabine.

Following that, patients identified as intermediate and high risk underwent a stem cell transplant. Patients were also randomized to receive sorafenib as an addition to standard treatment.

At a median follow-up of three years, patients randomized to receive sorafenib had improvements in event-free survival (40 percent vs 22 percent) and relapse-free survival (56 percent vs 38 percent) compared to those who did not receive sorafenib.

"These data constitute the first randomized evidence that kinase inhibitors work in AML," said study presenter Christoph Rollig, MD, of University Hospital Dresden in Germany.

This despite the fact that there was no evident overall survival advantage indicated from the data for those who received sorafenib. Furthermore, those patients also experienced far more adverse events in terms of side effects compared to the placebo arm.

Source: ASH 2014

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap